This case highlights how the exenatide patent filed by Amylin Pharmaceuticals led to a detailed examination of inventive step, therapeutic efficacy, and Section 3(d) objections, culminating in a significant Delhi High Court judgment in Nov. 2025
In a landmark decision concerning SPC for Durvalumab, the District Court of The Hague upheld the Dutch Intellectual Property Office’s (IPO) refusal to grant a Supplementary Protection Certificate (SPC) for AstraZeneca’s cancer immunotherapy drug Durvalumab, marketed as Imfinzi®. Durvalumab is an anti-PD-L1 antibody used in treating various cancers, and the refusal of SPC status has … Read more
UK Court of Appeal Judgment on Dapagliflozin Patent UK Court of Appeal Judgment: Dapagliflozin Patent In a recent landmark judgment, the UK Court of Appeal upheld the High Court’s April 2025 decision invalidating the UK equivalent patent of EP1506211B1 (expired on May 14, 2023) for Dapagliflozin and its associated Supplementary Protection Certificate (SPC) (Expiry Date: … Read more
